Stay updated on Nivolumab in Relapsed/Refractory DLBCL Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The site revision label in the page footer changed from v3.8.0 to v3.8.1.
    Difference
    0.0%
    Check dated 2026-11-18T02:58:22.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for the nivolumab study in relapsed or refractory diffuse large B-cell lymphoma, including study details, eligibility, locations, and measured outcomes.
    Difference
    66%
    Check dated 2026-11-11T02:00:13.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site revision changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-04T00:30:05.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    An NIH banner announces a terminology change from “Artificial Intelligence” to “Super Intelligence,” and the site revision number advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T00:31:25.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The site footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-07T00:33:33.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Users attempting to view the page now see a 403 Forbidden error instead of the study content, indicating restricted access. The change includes the 403 message and basic HTML scaffolding (doctype, head, and footer) to render an error page.
    Difference
    17%
    Check dated 2026-09-23T00:41:45.000Z thumbnail image

Stay in the know with updates to Nivolumab in Relapsed/Refractory DLBCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.